Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.35 |
| ▸ | CLK1 | P49759 | 3/20 | 0.35 |
| ▸ | CLK2 | P49760 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.35 |
| ▸ | CLK3 | P49761 | 2/20 | 0.35 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 4/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886981 | 1.00 | KDM4E (0.36) | KDM4EDYRK3CLK1CLK2DYRK1A | |
| SCHEMBL24366024 | 0.90 | MAPT (0.43) | KDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL25916910 | 0.90 | MAPT (0.43) | KDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL25324200 | 0.87 | MAPT (0.41) | KDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL25323936 | 0.84 | SLC5A2 (0.36) | KDM1ASLC5A2 | |
| SCHEMBL25919544 | 0.84 | SLC5A2 (0.36) | KDM1ASLC5A2 | |
| SCHEMBL25323938 | 0.84 | SLC5A2 (0.36) | KDM1ASLC5A2 | |
| SCHEMBL25320575 | 0.84 | SLC5A2 (0.37) | KDM1ASLC5A2MAT2AMLLT1 | |
| SCHEMBL25320574 | 0.84 | SLC5A2 (0.37) | KDM1ASLC5A2MAT2AMLLT1 | |
| SCHEMBL29347631 | 0.83 | TLR8 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | KDM4E 1882/4885DYRK3 3422/4885CLK1 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.